We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Renal replacement therapy (RRT) was initiated in cases of hepatorenal syndrome-acute kidney injury refractory to pharmacological therapy, particularly when accompanied by volume overload, severe ...

Three critically ill patients treated with procizumab experience a full reversal of cardiogenic shock in 48 hours.

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...

Arch Biopartners holds exclusive licensing for method-of-use patents to repurpose the therapy as a new AKI treatment. "Arch Biopartners’ Phase II AKI prevention trial begins patient recruitment" was ...

While hydroxychloroquine (HCQ) helps reduce disease flares in lupus, its effect on renal function in patients with lupus ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia ...

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The Company is developing a platform of novel drugs ...

Researchers discovered that mitochondria-rich extracellular vesicles (Ti-mitoEVs) from skeletal muscle can deliver healthy ...

Hypertension affects 6% of all children and adolescents and is increasing in prevalence. Research clarifies the long-term kidney consequences.

A team of researchers from Emory and Georgia Tech have developed a new device to help outdoor workers monitor how heat is ...

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during ...